Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474680 · ClinicalTrials.gov registry record
Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes
A clinical trial, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- 84
- Enrollment target
NCT02474680: Completed study, sponsored by Avera McKennan Hospital & University Health Center.
NCT02474680 is a clinical trial that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02474680 has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.
Primary Outcome
Compare depression scores at baseline and following pharmacogenetic-guided medication recommendation
Interventions
- GENETIC Pharmacogenetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2017-01-01 |
What the finished NCT02474680 record still lists
NCT02474680 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic testing is the first listed.
NCT02474680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02474680 about?
NCT02474680 is a clinical study titled "Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes". This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.
What is the current status of trial NCT02474680?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2015-11-01. Estimated completion is 2017-01-01.
What interventions are being tested in trial NCT02474680?
The interventions under investigation include: Pharmacogenetic testing (GENETIC).
Who is sponsoring clinical trial NCT02474680?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI